ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Research Progress on the Role and Mechanism of Flavonoids in Improving Metabolic Associated Fatty Liver Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoids are widely present in various plants and possess multiple biological activities, such as anti-inflammation, antioxidation and anticancer. In the realm of disease prevention and therapeutic interventions, a noteworthy function is assumed by these entities, evident from their significant research potentiality and intrinsic value. Characterized by an excessive lipid accumulation within the hepatic cells, metabolic associated fatty liver disease (MAFLD) manifests as a prevalent chronic ailment of the liver. The "multiple hits" theory suggests that its occurrence is the result of systemic homeostasis imbalance, influenced by factors such as abnormal lipid metabolism, inflammatory reaction, oxidative stress, insulin resistance, and gut microbiota. However, there are no effective clinical drugs for it. Recent studies have found that flavonoid active components can alleviate MAFLD through multiple pathways, including regulating abnormal lipid metabolism, inhibiting inflammatory response, alleviating oxidative stress, improving insulin resistance, regulating gut microbiota, and regulating liver autophagy. Therefore, this paper summarizes the pharmacological action and related mechanisms of flavonoid active components in improving MAFLD. This manuscript may provide a reference for seeking a novel therapeutic agent for MAFLD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.